Advice
Following an abbreviated submission.
New formulation of existing therapy.
Galantamine hydrobromide as Reminyl XLP®P prolonged-release capsules is accepted for use in NHS Scotland for the treatment of mild-to-moderately severe dementia in Alzheimer's disease in patients for whom therapy with galantamine is appropriate. It allows the reduction of dosing frequency to once daily and, at a given dose, involves no additional cost compared with immediate-release formulations of galantamine.
Download detailed advice33KB (PDF)
Medicine details
- Medicine name:
- Reminyl XL®
- SMC ID:
- 139/04
- Indication:
- Mild-to-moderately severe dementia in Alzheimer's disease
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Superseded
- Date advice published
- 13 June 2005